control group:TACE

11 trials

Sponsors

The First Affiliated Hospital of Zhejing University School of Medicine, Beijing Ditan Hospital, Capital Medical University, Shandong Cancer Prevention and Treatment Institute, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, The First Affiliated Hospital of Zhejiang University

Conditions

Hepatocellular CarcinomaHepatocellular carcinomaPrimary liver cancerhcchepatocellular carcinoma

Early Phase 1

A prospective, non-randomized, controlled trial of TACE in combination with PD-1 antibody (Camrelizumab) in the treatment of unresectable liver cancer

RecruitingChiCTR1900027427

The First Affiliated Hospital of Zhejing University School of Medicinehepatocellular carcinoma

Start: 2019-11-13Updated: 2019-11-18

The efficacy and safety of the combination of transcatheter arterial chemoembolisation with metronidazole in hepatocellular carcinoma

Active, not recruitingChiCTR2000029245

Beijing Ditan Hospital, Capital Medical UniversityHepatocellular carcinoma

Start: 2020-03-01Updated: 2020-01-20

A randomized, controlled, open-label clinical study of Transcatheter Arterial Chemoembolization (TACE) combined with Camrelizumab in the treatment of advanced Hepatocellular Carcinoma

RecruitingChiCTR2000031904

Shandong Cancer Prevention and Treatment InstituteHepatocellular Carcinoma

Start: 2020-04-15Updated: 2020-04-20

Effect of serum on fibroblasts and macrophages in patients with primary liver cancer before and after TACE and the effect of Jiedu recipe

Active, not recruitingITMCTR2200005664

Shanghai Changhai HospitalPrimary liver cancer

Start: 2022-04-01Updated: 2023-02-20

Phase 4

A prospective randomized controlled clinical study of the efficacy of lenvatinib combined with TACE versus TACE alone in patients with advanced first-line unresectable hepatitis B infection

Active, not recruitingChiCTR2000033343

The First Affiliated Hospital of Zhejiang UniversityHepatocellular carcinoma

Start: 2020-06-30Updated: 2020-06-01

Observational clinical study of camrelizumab combined with apatinib and TACE in adjuvant treatment of patients with high risk of recurrence after radical hepatocellular carcinoma

Active, not recruitingChiCTR2100049661

First Affiliated Hospital of Zhengzhou Universityhepatocellular carcinoma

Start: 2021-08-15Updated: 2022-04-19

Unknown Phase

Study of the combination of TACE with Apatinib in Patients with Hepatocellular Carcinoma Trial

RecruitingChiCTR-IOR-17010925

Zhongda Hospital,Affiliated to Southeast UniversityHepatocellular Carcinoma

Start: 2017-03-19Updated: 2017-04-18

Treatment of BCLC medium-term hepatocellular carcinoma (HCC) of randomized controlled study of Conventional TACE sequential microwave ablation (MWA) and conventional TACE alone

RecruitingChiCTR-IOR-17013743

Beijing You'an Hospital, Capital Medical Universityhcc

Start: 2017-12-08Updated: 2017-12-11

A randomized controlled trial of hepatectomy vesus transcatheter arterial chemoembolization for resectable BCLC Stage B/C hepatocellular carcinoma

Active, not recruitingChiCTR2000033231

The First Affiliated Hospital of Guangzhou University of Chinese MedicineHepatocellular carcinoma

Start: 2020-06-01Updated: 2020-05-25

The safety and efficacy of transarterial chemoembolization (TACE) + Lenvatinib + PD-1 antibody in the conversion-resection of advanced unresectable hepatocellular carcinoma: a multicenter prospective study

RecruitingChiCTR2100044466

West China Hospital of Sichuan Universityhepatocellular carcinoma

Start: 2020-10-21Updated: 2021-09-20

Therapy of primary liver cancer by green tea extract EGCG combined with transcatheter liver dynamic chemoembolization (TACE): a randomized controlled trial

Active, not recruitingChiCTR2100049363

The People's Hospital of Guangxi Zhuang Autonomous RegionPrimary liver cancer

Start: 2021-10-01Updated: 2023-07-10